» Articles » PMID: 1630819

Mechanism of Estrogen Activation of C-myc Oncogene Expression

Overview
Journal Oncogene
Date 1992 Aug 1
PMID 1630819
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

The estrogen receptor complex is a known trans-acting factor that regulates transcription of specific genes through an interaction with a specific estrogen-responsive cis-acting element (ERE). In previous studies we have shown that in estrogen-responsive human breast cancer cells estrogen rapidly activates c-myc expression. This activated expression occurs through enhanced transcription and does not require the synthesis of new protein intermediates; therefore, an ERE is present in the human c-myc gene regulatory region. To localize the ERE, constructs containing varying lengths of the c-myc 5'-flanking region ranging from -2327 to +25 (relative to the P1 promoter) placed adjacent to the chloramphenicol acetyl transferase reporter gene (CAT) were prepared. They were used in transient transfection studies in MCF-7 and HeLa cells co-transfected with an estrogen receptor expression vector. These studies reveal that all constructs containing the P2 promoter region exhibited estrogen-regulated CAT expression and that a 116-bp region upstream and encompassing the P2 TATA box is necessary for this activity. Analysis of this 116-bp region failed to identify a cis-acting element with sequences resembling the consensus ERE; however, co-transfection studies with mutant estrogen receptor expression vectors showed that the DNA-binding domain of the receptor is essential for estrogen-regulated CAT gene expression. We have also observed that anti-estrogen receptor complexes can weakly trans-activate from this 116-bp region but fail to do so from the ERE-containing ApoVLDLII-CAT construct. To explain these results we propose a new mechanism of estrogen trans-activation in the c-myc gene promoter.

Citing Articles

Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer.

Maharjan C, Mo J, Wang L, Kim M, Wang S, Borcherding N Cancers (Basel). 2022; 14(1).

PMID: 35008370 PMC: 8744660. DOI: 10.3390/cancers14010206.


Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells.

Steifensand F, Gallwas J, Bauerschmitz G, Grundker C Cells. 2021; 10(9).

PMID: 34572047 PMC: 8467413. DOI: 10.3390/cells10092398.


Metabolic Control by DNA Tumor Virus-Encoded Proteins.

Prusinkiewicz M, Mymryk J Pathogens. 2021; 10(5).

PMID: 34066504 PMC: 8148605. DOI: 10.3390/pathogens10050560.


Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies.

Rong C, Meinert E, Hess J Int J Mol Sci. 2018; 19(3).

PMID: 29498642 PMC: 5877574. DOI: 10.3390/ijms19030713.


SRC Increases mRNA Expression in Estrogen Receptor-Positive Breast Cancer via mRNA Stabilization and Inhibition of p53 Function.

Abdullah C, Korkaya H, Iizuka S, Courtneidge S Mol Cell Biol. 2017; 38(6).

PMID: 29263157 PMC: 5829483. DOI: 10.1128/MCB.00463-17.